MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamasurg.2023.1772

Медицинская библиотека · JAMA surgery · 2023

Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.

Kuemmel Sherko, Heil Joerg, Bruzas Simona, Breit Elisabeth, Schindowski Dorothea, Harrach Hakima, Chiari Ouafaa, Hellerhoff Karin, Bensmann Elena, Hanf Volker, Graßhoff Sven-Thomas, Deuschle Petra, Belke Kerstin, Polata Silke, Paepke Stefan, Warm Mathias, Meiler Johannes, Schindlbeck Christian, Ruhwedel Wencke, Beckmann Ulrike, Groh Ulrich, Dall Peter, Blohmer Jens-Uwe, Traut Alexander, Reinisch Mattea

СтатьяПеревод пока не подготовлен

Аннотация

IMPORTANCE

The increasing use of neoadjuvant systemic therapy (NST) has led to substantial pathological complete response rates in patients with initially node-positive, early breast cancer, thereby questioning the need for axillary lymph node dissection (ALND). Targeted axillary dissection (TAD) is feasible for axillary staging; however, data on oncological safety are scarce.

OBJECTIVE

To assess 3-year clinical outcomes in patients with node-positive breast cancer who underwent TAD alone or TAD with ALND.

DESIGN, SETTING, AND

PARTICIPANTS

The SenTa study is a prospective registry study and was conducted between January 2017 and October 2018. The registry includes 50 study centers in Germany. Patients with clinically node-positive breast cancer underwent clipping of the most suspicious lymph node (LN) before NST. After NST, the marked LNs and sentinel LNs were excised (TAD) followed by ALND according to the clinician's choice. Patients who did not undergo TAD were excluded. Data analysis was performed in April 2022 after 43 months of follow-up.

EXPOSURE: TAD alone vs TAD with ALND.

MAIN OUTCOMES AND MEASURES: Three-year clinical outcomes were evaluated.

RESULTS

Of 199 female patients, the median (IQR) age was 52 (45-60) years. A total of 182 patients (91.5%) had 1 to 3 suspicious LNs; 119 received TAD alone and 80 received TAD with ALND. Unadjusted invasive disease-free survival was 82.4% (95% CI, 71.5-89.4) in the TAD with ALND group and 91.2% (95% CI, 84.2-95.1) in the TAD alone group (P = .04); axillary recurrence rates were 1.4% (95% CI, 0-54.8) and 1.8% (95% CI, 0-36.4), respectively (P = .56). Adjusted multivariate Cox regression indicated that TAD alone was not associated with an increased risk of recurrence (hazard ratio [HR], 0.83; 95% CI, 0.34-2.05; P = .69) or death (HR, 1.07; 95% CI, 0.31-3.70; P = .91). Similar results were obtained for 152 patients with clinically node-negative breast cancer after NST (invasive disease-free survival: HR, 1.26; 95% CI, 0.27-5.87; P = .77; overall survival: HR, 0.81; 95% CI, 0.15-3.83; P = .74).

CONCLUSIONS AND RELEVANCE: These results suggest that TAD alone in patients with mostly good clinical response to NST and at least 3 TAD LNs may confer survival outcomes and recurrence rates similar to TAD with ALND.

Для цитирования: Kuemmel Sherko, Heil Joerg, Bruzas Simona, Breit Elisabeth, Schindowski Dorothea, Harrach Hakima, Chiari Ouafaa, Hellerhoff Karin, Bensmann Elena, Hanf Volker, Graßhoff Sven-Thomas, Deuschle Petra, Belke Kerstin, Polata Silke, Paepke Stefan, Warm Mathias, Meiler Johannes, Schindlbeck Christian, Ruhwedel Wencke, Beckmann Ulrike, Groh Ulrich, Dall Peter, Blohmer Jens-Uwe, Traut Alexander, Reinisch Mattea. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.. JAMA surgery. 2023. DOI: 10.1001/jamasurg.2023.1772.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.